Advisory Committees
Cellular, Tissue, and Gene Therapies Advisory Committee
The Cellular, Tissue and Gene Therapies Advisory Committee reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies and xenotransplantation products which are intended for transplantation, implantation, infusion and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions.
The Committee shall consist of a core of 13 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of cellular therapies, tissue transplantation, gene transfer therapies and xenotransplantation including biostatistics, bioethics, hematology/oncology, human tissues and transplantation, reproductive medicine, general medicine and various medical specialties including surgery and oncology, immunology, virology, molecular biology, cell biology, developmental biology, tumor biology, biochemistry, rDNA technology, nuclear medicine, gene therapy, infectious diseases, and cellular kinetics.
Additional Information
Roster of the Cellular, Tissue and Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee 2012 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee 2011 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee 2010 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee 2009 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee
Contact FDA
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448